Genomics England Enters Bioinformatics Partnership with Illumina
February 11 2016 - 4:00AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN) and Genomics England today
announce a partnership to develop a platform and knowledge base
that can be used to improve and automate genome interpretation. The
tools will operate within the Genomics England secure database to
enable researchers and clinicians to access information and reports
more readily.
Genomics England is partnering with Illumina to develop and
deliver systems for clinical interpretation, decision support and
knowledge curation for the 100,000 Genomes Project. This
non-exclusive partnership with Illumina will run in parallel with
the other clinical interpretation and bioinformatics providers
involved in the 100,000 Genomes Project.
Illumina and Genomics England will collaborate to develop a set
of informatics tools, which will support the delivery of genomic
clinical and research services at a population scale to the NHS
Genomic Medicine Centers and the Genomics England Clinical
Interpretation Partners. All of the tools will include open
application programming interfaces so that other bioinformatics
solution partners can continue to provide services within the
Project.
Under the terms of the partnership, Illumina will develop
interpretation and reporting tools for the purpose of delivering
reports on all genomes that are sequenced through the 100,000
Genomes Project. Genomics England will provide access
to whole genome sequence and de-identified phenotypic data for
the development of this suite of tools for personalised medicine.
The tools will be used to curate and manage the knowledge base of
information generated over the course of the project with a focus
on rare disease and common cancers. Illumina and Genomics
England have agreed to make available the clinical findings arising
from the 100,000 Genomes Project to approved users of the tools
developed through the collaboration.
The partnership also includes the ability for Genomics England
to work with Illumina’s other tools, NextBio® and BaseSpace®, for
data access and genomic data management. Illumina will make
available to Genomics England researchers and the GENE Consortium
part of the 100,000 Genomes dataset as a pilot within NextBio®
Clinical, which will enable cohort analysis of complex phenotypic
and genotypic information from de-identified genomes.
"Our partnership with Genomics England will help change the way
healthcare is practiced,” said Jay Flatley, Illumina’s Chairman and
CEO. “The development of our suite of technologies and platforms is
critical to enabling physicians in the future to make educated
diagnoses based on a patient’s genome which will lead to better
health outcomes.”
Sir John Chisholm, Executive Chairman of Genomics England said:
“This agreement allows Genomics England to access Illumina’s
bioinformatics knowledge and experience to support our ambitions of
transforming patient care and research. We are both committed to
patients benefiting from genomic analysis across the NHS and to
supporting clinicians and researchers in finding new genomic
insights. Illumina is our key sequencing partner and they are now
able to also support us, alongside our other partners, in solving
the challenges of delivering clinical reporting and knowledge
curation at a national scale.”
About Genomics England
Genomics England is a company owned by the Department of Health
and was set up to deliver the 100,000 Genomes Project. This
flagship project will sequence 100,000 whole genomes from NHS
patients and their families.
Genomics England has four main aims:
- to bring benefit to patients
- to create an ethical and transparent
programme based on consent
- to enable new scientific discovery and
medical insights
- to kickstart the development of a UK
genomics industry
The project is focusing on patients with rare diseases, and
their families, as well as patients with common cancers.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements include factors detailed in our filings with the
Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We do not intend to update any forward-looking
statements after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160211005220/en/
Genomics EnglandKatrina Nevin-Ridley, Director of
Communications0207 882
6493katrina.nevin-ridley@genomicsengland.co.uk@GenomicsEngland
#genomes100korIllumina, Inc.Investor RelationsRebecca
Chambers+1 858-255-5243rchambers@illumina.comorMediaDavid
Robertson, Europe, Middle East and Africa+44 (0)1223
824909drobertson@illumina.comorJennifer Temple+1
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024